Evidence map›Paper›PMID 33759087›Full record

ArticleInternational journal of hematology2021

A novel germline GATA2 frameshift mutation with a premature stop codon in a family with congenital sensory hearing loss and myelodysplastic syndrome.

Hideyuki Nakazawa, Tomomi Yamaguchi, Hitoshi Sakai, Masae Maruyama, Toru Kawakami, Fumihiro Kawakami, Sayaka Nishina, Masumi Ishikawa, Tomoki Kosho, Fumihiro Ishida

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hideyuki NakazawaDivision of Hematology, Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1, Matsumoto, Nagano, 3908621, Japan. hnaka@shinshu-u.ac.jp.ORCID http://orcid.org/0000-0002-6457-5052
Tomomi YamaguchiCenter for Medical Genetics, Shinshu University Hospital, Matsumoto, Japan.
Hitoshi SakaiDivision of Hematology, Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1, Matsumoto, Nagano, 3908621, Japan.
Masae MaruyamaDepartment of Biomedical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto, Japan.
Toru KawakamiDivision of Hematology, Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1, Matsumoto, Nagano, 3908621, Japan.
Fumihiro KawakamiDivision of Hematology, Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1, Matsumoto, Nagano, 3908621, Japan.
Sayaka NishinaDivision of Hematology, Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1, Matsumoto, Nagano, 3908621, Japan.
Masumi IshikawaCenter for Medical Genetics, Shinshu University Hospital, Matsumoto, Japan.
Tomoki KoshoCenter for Medical Genetics, Shinshu University Hospital, Matsumoto, Japan.
Fumihiro IshidaDivision of Hematology, Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1, Matsumoto, Nagano, 3908621, Japan.
Shinshu University · JPShinshu University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GATA2 is a zinc-finger transcription factor regulating early hematopoiesis and developmental processes. Heterozygous germline mutations in GATA2 underlie a pleiotropic autosomal dominant disorder, GATA2 deficiency syndrome. The wide spectrum of its clinical features involves familial predisposition to myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) and multiorgan dysfunction, including congenital sensorineural hearing loss (CSHL). We herein report a pedigree with a novel germline frameshift mutation presenting as CSHL and familial MDS. The proband was a 46-year-old man, and his daughter also presented with an identical set of clinical syndromes. Target DNA sequencing identified a novel eight-nucleotide duplicative insertion at exon 5 (NM_032638.4:c.1126_1133dup:p.Lys378Asnfs*12) of the GATA2 gene. RT-PCR and subcloning analysis showed that the frameshift might result in a truncated mutation with an early stop codon without interfering with the predicted splice site. The predicted mutant protein had 388 amino acids and in silico analysis showed the variant was considered deleterious. This mutation was not detected in unaffected family members. Its deleterious effect is highly likely to have portended the familial MDS and CSHL in this pedigree. Genetic testing among suspected individuals may be warranted for adequate management, including timely transplantation.

Indexed as

Codon, NonsenseGerm-Line MutationBiomarkersBiopsyBone MarrowDNA Mutational AnalysisGATA2 Transcription FactorHearing Loss, SensorineuralHumansImmunohistochemistryMaleMiddle AgedMyelodysplastic SyndromesPedigreeBiomarkersCodon, NonsenseGATA2 protein, humanGATA2 Transcription FactorCongenital sensory hearing lossFamilial MDSGATA2Germline mutation

Identifiers

PMID33759087
OpenAlexW3138893643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.